Possibilities for correcting hepatotoxic reactions during therapy in patients with COVID-19 (case report)

In 2020, a pandemic of the new coronavirus infection (COVID-19) began. Treatment of this infection is limited by the lack of effective etiological treatment, which requires the selection of empirical and symptomatic therapy. The obtained some effectiveness of the use of antimalarial drugs, antiretroviral drugs in combination with antibacterial therapy made it possible to recommend it for use in the treatment regimen for patients with COVID-19. However, these drugs provoke the development of undesirable side reactions that require correction to continue treatment. Considering the need to use complex therapy in the treatment of patients with COVID-19 and the direct effect of the virus on liver cells, the likelihood of developing hepatotoxicity is quite high. The described cases of liver damage are characterized by impaired functional activity, an increase in the level of liver function tests, the development of small-drop fatty infiltration and a mild inflammatory reaction in the liver lobules. The development of these complications requires the hepatoprotective drugs, which increase the liver’s resistance to the damaging effects of various pathogens and help restore the functional activity of hepatocytes. According to the conducted studies, hepatotropic drug inosine+ + meglumine + methionine + nicotinamide + succinic acid and reamberin contribute to the normalization of lipid metabolism, a decrease in the level of enzyme markers of liver damage. The article presents the complex treatment with lopinavir + ritonavir. Thanks to hepatoprotective therapy, a week later, a decrease in ALT, alpha-amylase, blood counts to normal values was achieved.

antiviral therapy, COVID-19, hepatoprotectors, hepatotoxicity

1. WHO. Coronavirus disease (COVID-19) Pandemic. Geneva: WHO; 2020. https://www.who.int/emergencies/diseases/novel-coronavirus-2019 (01 August 2020).

2. CORONAVIRUS (COVID-19). https://coronavirus-monitor.ru/ (01 August 2020).

3. Starshinova AA, Kushnareva EA, Malkova AM, et al. New coronaviral infection: features of clinical course, capabilities of diagnostics, treatment and prevention in adults and children. Voprosy sovremennoj pediatrii=Current Pediatrics. 2020; 19 (2): 123–131. In Russian

4. Shchelkanov MYu, Popova AYu, Dedkov VG, et al. History of investigation and current classification of coronaviruses (Nidovirales: Coronaviridae). Infekciya i immunitet=Infection and Immunity. 2020; 10 (2): 221–246. In Russian

5. Lau SKP, Lee P, Tsang AKL, et al. Molecular epidemiology of human coronavirus OC43 reveals evolution of different genotypes over time and recent emergence of a novel genotype due to natural recombination. J Virol. 2011; 85 (21): 11325–11337.

6. Rothe C, Schunk M, Sothmann P, at al. Transmission of 2019-nCoV infection from an asymptomatic contact in Germany. N Engl J Med. 2020; 382 (10): 970–971.

7. Wölfel R, Corman VM, Guggemos W, et al. Virological assessment of hospitalized cases of coronavirus disease 2019. 2020. MedRxiv. doi: 10.1101/2020.03.05.20030502.

8. Ong SWX, Tan YK, Chia PY, et al. Air, surface environmental, and personal protective equipment contamination by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from a symptomatic patient. JAMA. 2020; 323 (16): 1610–1612.

9. Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020; 579 (7798): 265–269.

10. Letko M, Marzi A, Munster V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat Microbiol. 2020; 5 (4): 562–569.

11. Giani M, Seminati D, Lucchini A, et al. Exuberant plasmocytosis in bronchoalveolar lavage specimen of the first patient requiring extracorporeal membrane oxygenation for SARS-CoV-2 in Europe. J Thorac Oncol. 2020; 15 (5): e65–e66.

12. Liu W, Li H. COVID-19: Attacks the 1-beta chain of hemoglobin and captures the porphyrin to inhibit human heme metabolism. 2020. ChemRxiv. doi: 10.26434/chemrxiv.11938173.v5.

13. Geleris J, Sun Y, Platt J, et al. Observational study of hydroxychloroquine in hospitalized patients with COVID-19. N Engl J Med. 2020; 382 (25): 2411–2418.

14. Cavalli G, De Luca G, Campochiaro C, et al. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. Lancet Rheumatol. 2020; 2 (6): e325–e331.

15. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA 2020; 323 (13): 1239–1242.

16. Li Y, Xie Z, Lin W, et al. Efficacy and safety of lopinavir/ritonavir or arbidol in adult patients with mild/ moderate COVID-19: an exploratory randomized controlled trial. 2020. Med (N Y). doi: 10.1016/j.medj.2020.04.001.

17. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of COVID-19 — Preliminary Report. N Engl J Med. 2020; 383 (10): 994.

18. Clinical study evaluating the efficacy of faviprevir in COVID-19 treatment. https://www.clinicalkey.com/#!/content/clinical_trial/24-s2.0-NCT04351295. (1 August 2020).

19. Geleris J, Sun Y, Platt J, et al. Observational study of hydroxychloroquine in hospitalized patients with COVID-19. N Engl J Med. 2020; 382 (25): 2411–2418.

20. Temporary guidelines “Prevention, diagnosis and treatment of new coronavirus infection (COVID-19)” (version 6 of 04.24.2020). P. 165. In Russian

21. Starshinova AA, Belyaeva EN, Panteleev AM, et al. Use of hepatoprotectors during tuberculosis chemotherapy: review of the Russian and international studies. Tuberkulez i bolezni legkih= Tuberculosis and lung diseases. 2018; 96 (10): 63–69. In Russian

22. Boettler T, Newsome PN, Mondelli MU, et al. Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper. JHEP Rep. 2020; 2 (3): 100113.

23. Fan Z, Chen L, Li J, et al. Clinical features of COVID-19-related liver damage. Clin Gastroenterol Hepatol. 2020; 18 (7): 1561–1566.

24. Shabanov PD, Ganapol’skij VP, Zhumasheva AB, et al. Trekrezan as a metabolic activator with the properties of a meteoadaptogen, psychoenergizer and immunomodulator. Vestnik Rossijskoj voenno-medicinskoj akademii= Bulletin of the Russian Military Medical Academy. 2006; 15 (1): 53–57. In Russian

25. Ivanova DA, Kudlay DA, Borisov SE, et al. Effect of silymarin for the prevention of drug-induced liver injury in tuberculosis patients. Tuberkulez i social’no znachimye zabolevaniya=Tuberculosis and socially significant diseases. 2017; 4: 28–33. In Russian

26. Ilchenko LYu, Okovityi SV. Remaxol: mechanisms of action and application in real clinical practice. Part II. Arhiv vnutrennej mediciny=Archive of Internal Medicine. 2016; 6(3): 8–18. In Russian

27. Ilchenko LYu, Okovityi SV. Remaxol: mechanisms of action and application in real clinical practice. Part I. Arhiv vnutrennej mediciny=Archive of Internal Medicine. 2016; 6 (2): 16–22. In Russian

28. Sologub TV, Sukhanov DS, Petrov AYu, et al. The risk of poor outcomes in pharmacoeconomic analysis and the evaluation of the safety of remaxol in therapy for chronic viral hepatic lesions (according to the materials of multicenter randomized clinical studies). Epidemiologiya i infekcionnye bolezni=Epidemiology and infectious diseases. 2010; 1: 61–64. In Russian

29. Danan G, Teschke R. RUCAM in drug and herb induced liver injury: the update. Int J Mol Sci. 2015; 17 (1): 14.

30. Su T-H, Kao J-H. The clinical manifestations and management of COVID-19-related liver injury. J Formos Med Assoc. 2020; 119 (6): 1016–1018.

31. Chai X, Hu L, Zhang Y, et al. Specific ACE2 expression in cholangiocytes may cause liver damage after 2019-nCoV infection. 2020. bioRxiv. doi: 10.1101/2020.02.03.931766.

32. Zhang H, Kang Z, Gong H, et al. The digestive system is a potential route of 2019-nCov infection: a bioinformatics analysis based on single-cell transcriptomes. 2020. bioRxiv. doi: 10.1101/2020.01.30.927806.

33. Ji D, Qin E, Xu J, et al. Implication of non-alcoholic fatty liver diseases (NAFLD) in patients with COVID-19: a preliminary analysis. J Hepatol. 2020; 73 (2): 451–453.

34. Temporary guidelines “Prevention, diagnosis and treatment of new coronavirus infection (COVID-19)” (version 8 of 03.09.2020). P. 226. In Russian